External Validation of the “Walking Estimated Limitation Calculated by History” (WELCH) Questionnaire in Patients with Claudication

Ábrahám, Pierre; Godet, R; Harbonnier, M.; Lanéelle, Damien; Lefthériotis, Georges; Ouédraogo, Nafi

doi:10.1016/j.ejvs.2013.11.010

Cited by 11 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is important to note that due to the low educational levels in patients who utilize the public health system, our version of the questionnaire uses an interview format, which is different than the self-completed format of other WELCH versions. 16 , 17 , 21 , 22 Thus, in order to obtain similar results to those described in this study, the Brazilian Portuguese WELCH version should be applied using an interview format.…”

Section: Discussionmentioning

confidence: 61%

“…The Walking Estimated-Limitation Calculated by History (WELCH) questionnaire was recently proposed as a new simple and easily scored four-item questionnaire to assess walking impairment in patients with IC. Although the WELCH questionnaire has been validated in other languages 16 , 17 , it has not yet been translated and validated into the Portuguese language, limiting its use in Brazilian patients with IC. Thus, the aim of the present study was to analyze the psychometric properties of a Brazilian Portuguese version of the WELCH questionnaire in patients with IC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of a Brazilian Portuguese Version of the Walking Estimated-Limitation Calculated by History (WELCH)

Cucato¹,

Correia²,

Farah³

et al. 2016

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

BackgroundThe Walking Estimated-Limitation Calculated by History (WELCH) questionnaire has been proposed to evaluate walking impairment in patients with intermittent claudication (IC), presenting satisfactory psychometric properties. However, a Brazilian Portuguese version of the questionnaire is unavailable, limiting its application in Brazilian patients.ObjectiveTo analyze the psychometric properties of a translated Brazilian Portuguese version of the WELCH in Brazilian patients with IC.MethodsEighty-four patients with IC participated in the study. After translation and back-translation, carried out by two independent translators, the concurrent validity of the WELCH was analyzed by correlating the questionnaire scores with the walking capacity assessed with the Gardner treadmill test. To determine the reliability of the WELCH, internal consistency and test-retest reliability with a seven-day interval between the two questionnaire applications were calculated.ResultsThere were significant correlations between the WELCH score and the claudication onset distance (r = 0.64, p = 0.01) and total walking distance (r = 0.61, p = 0.01). The internal consistency was 0.84 and the intraclass correlation coefficient between questionnaire evaluations was 0.84. There were no differences in WELCH scores between the two questionnaire applications.ConclusionThe Brazilian Portuguese version of the WELCH presents adequate validity and reliability indicators, which support its application to Brazilian patients with IC.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Validation of a Brazilian Portuguese Version of the Walking Estimated-Limitation Calculated by History (WELCH)

Cucato¹,

Correia²,

Farah³

et al. 2016

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

“…The secondary outcomes of the study will be the maximal duration of walking, variation in TcPO 2 , the ABI value measured during the Strandness exercise test, variations in peak VO 2 , endothelial function (using the EndoPAT® system), cardiovascular risk factors (Body Mass Index, lipids (LDL-cholesterol, HDL-cholesterol, triglycerides), resting arterial blood pressure, glycaemic status (fasting glycaemia, glycosylated haemoglobin (HbA1c) level), and the scores obtained in the WELCH questionnaire [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

“…The WELCH (Walking Estimated Limitation Calculated by History) questionnaire is a self-administered questionnaire validated in French and specific to PAD [ 22 ]. Via four questions (‘duration of slow walking’ , ‘duration of moderate walking’ , ‘duration of fast walking’ , ‘comparison of one’s walking speed with that of one’s entourage’), it evaluates the symptoms of the claudication in everyday life.…”

Section: Methodsmentioning

confidence: 99%

The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study

Besnier

Sénard

Grémeaux³

et al. 2017

Trials

View full text Add to dashboard Cite

BackgroundIn patients with peripheral arterial disease (PAD), walking improvements are often limited by early pain onset due to vascular claudication. It would thus appear interesting to develop noninvasive therapeutic strategies, such as transcutaneous electrical nerve stimulation (TENS), to improve the participation of PAD patients in rehabilitation programmes, and thus improve their quality of life. Our team recently tested the efficacy of a single 45-min session of 10-Hz TENS prior to walking. TENS significantly delayed pain onset and increased the pain-free walking distance in patients with class-II PAD. We now seek to assess the efficacy of a chronic intervention that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in Leriche-Fontaine stage-II PAD patients.Methods/designThis is a prospective, double-blind, multicentre, randomised, placebo-controlled trial. One hundred subjects with unilateral PAD (Leriche-Fontaine stage II) will be randomised into two groups (1:1). For the experimental group (TENS group): the treatment will consist of stimulation of the affected leg (at a biphasic frequency of 10 Hz, with a pulse width of 200 μs, maximal intensity below the motor threshold) for 45 min per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week. For the control group (SHAM group): the placebo stimulation will be delivered according to the same modalities as for the TENS group but with a voltage level automatically falling to zero after 10 s of stimulation. First outcome: walking distance without pain. Secondary outcomes: transcutaneous oxygen pressure (TcPO2) measured during a Strandness exercise test, peak oxygen uptake (VO2 peak), endothelial function (EndoPAT®), Ankle-brachial Pressure Index, Body Mass Index, lipid profile (LDL-C, HDL-C, triglycerides), fasting glycaemia, HbA1c level, and the WELCH questionnaire.DiscussionTENS-PAD is the first randomised controlled trial that uses transcutaneous electrical therapy as an adjuvant technique to improve vascular function in the treatment of PAD. If the results are confirmed, this technique could be incorporated into the routine care in cardiovascular rehabilitation centers and used in the long term by patients to improve their walking capacity.Trial registrationClinicalTrials.gov, ID: NCT02678403. Registered on 9 February 2016. Sponsor: Toulouse University Hospital.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-017-1997-1) contains supplementary material, which is available to authorized users.

show abstract

“…Az alsó végtag funkcionális kapacitását a WELCH-(Walking Estimated-Limitation Calculated by History) kérdőívvel értékeltük. Ennek használatához a kérdőív fejlesztője az írásos hozzájárulását adta [21]. Alkalmazása előtt Brislin visszafordítási módszerét alkalmaztuk az eszköz magyar változatának elkészítéséhez [22].…”

Section: A Betegek éRtékeléseunclassified

A cilostazol diabeteses betegekben is javítja az életminőséget és az alsó végtagi funkcionális kapacitást

Farkas

Járai

2020

View full text Add to dashboard Cite

Absztrakt: Bevezetés: A claudicatio intermittens jelentős negatív hatással van a betegek életminőségére. A különböző revascularisatiós eljárások és a noninvazív orvosi kezelések javíthatják a betegek járását. A cilostazol I.A ajánlással rendelkezik a claudicatio intermittens kezelésére. Célkitűzés: Vizsgálatunk célja a 3 hónapos cilostazolkezelésnek az egészséggel kapcsolatos életminőségre és az alsó végtag funkcionális kapacitására gyakorolt hatásának értékelése a klinikai gyakorlatban, claudicatio intermittensben szenvedő diabeteses (DM) és nem diabeteses (NDM) betegek körében. Módszer: A tanulmány multicentrikus, beavatkozással nem járó vizsgálat, amelybe 812, ambuláns kezelés alatt álló, perifériás verőérbetegségben szenvedő beteg (Fontaine II. stádium, átlagéletkor: 67,17 év, férfi/nő: 58,25/41,75%, 318 diabeteses) került beválasztásra, akik cilostazolkezelést kaptak (50 vagy 100 mg naponta kétszer) 3 hónapig. Az életminőséget az EQ-5D-3L-kérdőívvel, a funkcionális kapacitást a WELCH-kérdőívvel értékeltük. A fájdalommentes és maximális járástávolságnak, valamint a boka-kar indexnek a mérése megtörtént a vizsgálat indulásakor és a 3 hónapos kezelés után. Eredmények: A vizsgálat befejezése után az EQ-5D-index javult (kiindulási érték: NDM –0,45 ± 0,22, DM –0,48 ± 0,23, 3. hónap: –0,24 ± 0,18, –0,27 ± 0,19; p<0,0001), és a WELCH-pontszám szintén szignifikánsan nőtt (kiindulási érték: NDM 20 ± 14, DM 18 ± 14; 3. hónap: 33 ± 19, 29 ± 16; p<0,0001) mindkét betegcsoportban. Mind a fájdalommentes, mind a maximális járástávolság nőtt: NDM 59,2% (medián: 50,0%), 46,58 (medián: 40,51%), és DM 42,85% (medián: 43,33%), 41,61% (medián: 34,68%) (p<0,001). Következtetés: 3 hónapos cilostazolkezelés javította az életminőséget és az alsó végtagi funkcionális kapacitást claudicatio intermittensben szenvedő betegekben, diabetes esetén is. A WELCH-kérdőív hasznos eszköznek bizonyult a klinikai gyakorlatban a claudicatio kezelése során a járóképesség értékelésére. Orv Hetil. 2020; 161(38): 1637–1645.

show abstract

External Validation of the “Walking Estimated Limitation Calculated by History” (WELCH) Questionnaire in Patients with Claudication

Cited by 11 publications

References 16 publications

Validation of a Brazilian Portuguese Version of the Walking Estimated-Limitation Calculated by History (WELCH)

Validation of a Brazilian Portuguese Version of the Walking Estimated-Limitation Calculated by History (WELCH)

The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study

A cilostazol diabeteses betegekben is javítja az életminőséget és az alsó végtagi funkcionális kapacitást

Contact Info

Product

Resources

About